読み込み中
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
前日終値
$1.74
−$0.07 · -3.87%
時間外
$1.76
+$0.02 · +1.15%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
58
適正価値
センチメント
39
弱気
リスク
73
高リスク
モメンタム
48
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7556.42万 USD | 1012万 USD | 169.8万 USD | 619.4万 USD | 150.7万 USD |
| 売上原価 | 9659.42万 USD | 1.41億 USD | — | — | — |
| 粗利益 | −2103万 USD | −1.31億 USD | 169.8万 USD | 619.4万 USD | 150.7万 USD |
| 研究開発 | 1.29億 USD | 1.58億 USD | 1.3億 USD | 1.17億 USD | 1.11億 USD |
| 販売・一般管理 | 1.32億 USD | — | 4674.5万 USD | 3189.9万 USD | 3186.5万 USD |
| 営業費用 | 2.6億 USD | 1.11億 USD | 1.81億 USD | 1.49億 USD | 1.42億 USD |
| 受取利息 | 1902.44万 USD | 3235.5万 USD | 1350.5万 USD | 170.8万 USD | 26.2万 USD |
| 支払利息 | 3675.57万 USD | 929.4万 USD | 4506.7万 USD | 890.5万 USD | 110.5万 USD |
| 減価償却費と償却費 | 981.4万 USD | 771.6万 USD | 656.5万 USD | 742.2万 USD | 845.8万 USD |
| 営業利益 | −2.81億 USD | −2.41億 USD | −1.8億 USD | −1.43億 USD | −1.4億 USD |
| 純利益 | −2.88億 USD | −2.21億 USD | −2.08億 USD | −1.49億 USD | −1.42億 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.87
上昇余地（409.77%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB240.92万0.02%108.2億 USD0.44%$204.26-1.08%
Tema Oncology ETFCANC48.09万0.24%2.05億 USD0.99%$40.5781-0.50%
State Street SPDR S&P International Small Cap ETFGWX18.31万0.02%9.15億 USD0.40%$45.26-0.66%
Invesco NASDAQ Future Gen 200 ETFQQQS9.18万0.40%2275.83万 USD0.20%$41.414-1.73%
ActivePassive International Equity ETFAPIE5.52万—11.41億 USD0.45%$38.40-0.41%
Invesco Nasdaq Biotechnology ETFIBBQ2.7万0.02%1.12億 USD0.19%$34.2482-1.07%
ProShares Ultra Nasdaq BiotechnologyBIB1.34万0.01%9320.36万 USD1.19%$108.79-1.90%iShares Biotechnology ETFIBBTema Oncology ETFCANCState Street SPDR S&P International Small Cap ETFGWXInvesco NASDAQ Future Gen 200 ETFQQQSActivePassive International Equity ETFAPIEInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
